Nov 25 (Reuters) - Adamis Pharmaceuticals Corp said on Monday its opioid overdose treatment was rejected by the U.S. Food and Drug Administration.
In a letter to the company, the FDA raised questions about the treatment’s chemistry and manufacturing but not about its safety or effectiveness, Adamis said.
The drug Zimhi is a naloxone pre-filled single dose syringe used for the emergency treatment of known or suspected opioid overdose.
Reporting by Shivani Singh and Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.